Your browser doesn't support javascript.
loading
IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4.
Huo, Jia; Fu, Lijun; Jin, Mengyuan; Li, Zhaoming; Zhang, Mingzhi.
Afiliación
  • Huo J; Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
  • Fu L; Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.
  • Jin M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Road, Zhengzhou, Henan, 450000, China.
  • Li Z; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Road, Zhengzhou, Henan, 450000, China.
  • Zhang M; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Road, Zhengzhou, Henan, 450000, China. mingzhi_zhang1@163.com.
Invest New Drugs ; 40(3): 537-545, 2022 06.
Article en En | MEDLINE | ID: mdl-35226228
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interleucina-10 / Proteínas Asociadas a Resistencia a Múltiples Medicamentos / Desoxicitidina / Linfoma Extranodal de Células NK-T Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Invest New Drugs Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Interleucina-10 / Proteínas Asociadas a Resistencia a Múltiples Medicamentos / Desoxicitidina / Linfoma Extranodal de Células NK-T Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Invest New Drugs Año: 2022 Tipo del documento: Article País de afiliación: China